|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's Range||67.81 - 68.53|
|52 Week Range||52.51 - 80.71|
|PE Ratio (TTM)||19.62|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Moody's Investors Service (Moody's) announced today that it assigned Baa3 ratings to DaVita Inc.'s incremental senior secured term loan A add-ons. There is no change to DaVita's existing ratings, including its Ba2 Corporate Family Rating, Ba2-PD Probability of Default Rating, Baa3 ratings on its other senior secured credit facilities and the Ba3 ratings on its unsecured notes.
The Denver-based company said it had net income of 98 cents per share. Earnings, adjusted to account for discontinued operations, came to $1.05 per share. The results topped Wall Street expectations. The ...
The program shows "how transplantation and dialysis can work together instead of operating in separate silos."
There aren't many end-stage renal disease patients — it's less than 1 percent of the Medicare population — but they're expensive to insurers: Each patient's annual care cost an average $84,550 in 2013, about 7 percent of all Medicare fee-for-service spending.
UnitedHealth Group’s Optum is signaling more acquisitions of medical providers lie ahead after UnitedHealth CEO Dave Wichman said executives will be "strong deployers of capital."
In its latest issue of Healthcare Quarterly, Moody's Investors Service examines how planned mergers between health insurers and other healthcare companies, as well as potential new entrants to the US healthcare ...
Disruptors are circling the health-care industry. UnitedHealth Group Inc., the biggest U.S. health insurer, has built an army of tens of thousands of physicians to fend off invaders.
This could indicate that investors who seek to profit from falling equity prices are not currently targeting DVA. Over the last one-month, outflows of investor capital in ETFs holding DVA totaled $3.27 billion.
Davita's kidney care unit is gaining prominence worldwide. However, the company is grappling with labor-union woes in California and Ohio.
Let's put DaVita (DVA) stock into this equation and find out if it is a good choice for value-oriented investors right now.
Stocks that moved substantially or traded heavily on Tuesday: Qualcomm Inc., down $3.11 to $59.70 President Donald Trump blocked Broadcom's effort to buy the rival chipmaker, citing national security concerns. ...
This could indicate that investors who seek to profit from falling equity prices are not currently targeting DVA. Over the last one-month, outflows of investor capital in ETFs holding DVA totaled $16.83 billion.
DaVita Inc (NYSE:DVA) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017.
US not-for-profit hospitals will face greater competition, risk of volume declines and margin erosion as the nation's largest commercial health insurers aggressively pursue growth strategies, Moody's Investors ...
Flush with $4.9 billion in cash from the pending sale of its medical group and as much as $130 million in expected benefits from federal tax reform, DaVita Inc. CEO Kent Thiry said Tuesday that the company will look to repurchase shares, grow its kidney-care business and make “a limited number of investments” in other health-care companies. The comments came during a quarterly earnings call — the Denver-based kidney-care provider’s first since it announced the sale of its disappointing managed-care unit, DaVita Medical Group, in December to Optum. Thiry told the Denver Business Journal the day after the sale announcement that the company will look at the possible acquisition of companies in other areas of health care andt, already had begun looking at opportunities that it could integrate into its existing divisions.
Yahoo Finance's Jared Blikre and Alexis Christoforous break down the latest market action.